Sanofi-aventis has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix® product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent. Forward-looking statements: This press release contains forward-look
Rhodia announced today that it has commenced legal proceedings in the United States of America and Brazil against sanofi-aventis as former owner or operator of the Silver Bow (United States of America) and Cubatao (Brazil) sites to seek to obtain compensation for environmental liabilities related to these two sites. Aventis and Rhodia signed a final settlement agreement on March 27, 2003 pursua
According to a decision by the European Commission announced today, various producers of MCAA (monochloroacetic acid), an organic chemical used as intermediate in the manufacture of various products, have been fined. This decision was made further to an investigation regarding alleged arrangements affecting competition in certain markets for MCAA. Among those producers, Hoechst, an affiliate of
Sanofi-aventis announced today that the European Commission has approved 2 new indications for Taxotere® (docetaxel) Injection Concentrate for treatment of breast cancer. The first granted TAXOTERE , in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer. A second granted TAXOTERE , in combination with Herceptin (tr
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that, following a review of the Vascular Endothelial Growth Factor (VEGF) Trap program, they have reaffirmed their commitment to develop the VEGF Trap in oncology in collaboration with Regeneron Pharmaceuticals Inc. (Nasdaq: REGN). The companies will evaluate the VEGF Trap in a variety of cancer types, both in single-agent studies and in
Sanofi-aventis announced today the official change in the legal denomination of the Aventis Pasteur company, which will henceforth be named sanofi pasteur. The General Meeting of Shareholders of Aventis Pasteur, held in December 2004, voted the change in name from Aventis Pasteur to sanofi pasteur. The Aventis Pasteur MSD joint venture, equally owned by Aventis Pasteur and Merck & Co. Inc.
Jean-François DEHECQ, Chairman and CEO of Sanofi-aventis, is currently accompanying Philippe DOUSTE-BLAZY, French Minister for Humanitarian aid, Health and the Family in his mission to Colombo, Sri-Lanka, to provide six tons of Sanofi-aventis medicines, consisting of 70,000 packs of antibiotics, anti-diarrhea medicines and antibacterial treatments. Within the framework of a humanitarian initia
Sanofi-aventis announced today its plan to reimburse the short-term tranche of the syndicated credit line which was put in place in April 2004 to finance the acquisition of Aventis (Tranche A). This 5 billion-Euro tranche is maturing on January 24, 2005. The company had an option to extend maturity for a maximum of one year. However, in order to optimise its financing costs, sanofi-aventis has
Sequential Taxotere following epirubicin-based regimen demonstrates survival advantage Aventis, part of the sanofi-aventis Group announced today that the results of a large phase III study demonstrated that sequential TAXOTERE (docetaxel) Injection Concentrate-based regimen significantly improved overall survival of women with operable, node-positive early stage breast cancer compared to a s
Since April 26, 2004, when Sanofi-Synthélabo and Aventis agreed to create sanofi-aventis, it has been confirmed that the headquarters of the new sanofi-aventis Group is to be located in Paris. Sanofi-aventis announced today that the Aventis site located in Schiltigheim will cease its activity during the course of next year. The business activity will be transfered to Paris. The French Wor
Aventis, part of the sanofi-aventis Group, announced today that it had sent to Genta a notice of termination of the agreements entered into by the two companies in 2002 and concerning the development of Genasense® (oblimersen sodium). At the time the agreements with Genta were entered into, Aventis was seeking a late-stage development opportunity that could potentially provide for a near term
~ First Major Advance in the Postsurgical Treatment Of Early-Stage Colon Cancer in More Than a Decade ~ Sanofi-Synthelabo, a member of the sanofi-aventis Group announced today that the US Food and Drug Administration (FDA) has approved ELOXATIN, in combination with conventional chemotherapy (infusional 5-fluorouracil/leucovorin, known as 5-FU/LV), for the adjuvant (postsurgical) treatment of
